Scientific Program

To download the last version of the Scientific Program, please click here PDF

Tuesday, September 18th

  Activity
8:30-9:15

Key Lecture:

Kewal K. Jain/Switzerland- “Integration and translation of OMICs technologies (genomics, proteomis, metabolomics, etc) using systems biology approach to develop personalized medicines (from discovery to clinical applications)”.
IMMUNO-ONCOLOGY: Leading edge cell-based Immunotherapy
Chairman: Jose R Conejo-Garcia (USA) and Silvio E Perea (Cuba)
9:30-10:00 Kelley Parato/ BioCanRx, Otawa, Canada - Building a CAR: Structural Considerations.
10:10-10:40 Jose R Conejo Garcia/ Moffitt Cancer Center, Tampa, USA - Chimeric Endocrine Receptors targeting the FSH Receptor enable T cells to block ovarian cancer progression without off-tumor toxicity.
10:50-11:20 Prof. Renier Brentjer /USA - CARS and ARMORED CARS.
11:30-11:45 Coffe Break

Active and Passive Cancer Immunotherapy
Chairman: Renier Brentjer (USA) and Tania Crombet (Cuba)
11:45-12:05 Yanelys Morera/ Center for Genetic Engineering and Biotechnology, Havana, Cuba - HEBERSaVax: Research and development of a promising therapeutic cancer vaccine from the laboratory to the clinic.
12:10-12:30 Javier Sanchez/Center for Genetic Engineering and Biotechnology, Havana, Cuba - Characteristics of the specific humoral response elicited in patients with advanced solid tumors using a VEGF-based vaccine, at different antigen doses and with two distinct adjuvants.
12:35-13:00 Tania Crombet/Center for Molecular Immunology, Havana, Cuba - Active Immunotherapy for Non-Small Cell Lung Cancer (NSCLC): Center for Molecular Immunology (CIM) Approaches.

Wednesday, September 19th

  Activity
8:30-9:15

Key Lecture:

Bob Williamson/Australia- “Personalised Medicine: the Application of Genomics to Health Care”.
Emerging Molecular Targets for Cancer Therapy
Chairman: Katherine Borden (Canada) and Yasser Perera (Cuba)
9:30-10:00 Frank Rauscher III/The Wistar Cancer Institute, Pennsylvania, USA - Gene regulation and crosstalk amongst innate immune factors in the Tumor Microenvironment: treating the tumor as an organ.
10:10-10:40 Katherine Borden/Institute for Research in Immunology, University of Montreal, Montreal, Canada - Targeting post-transcriptional regulation in cancer.
10:50-11:20 Silvio Perea/Center for Genetic Engineering and Biotechnology, Havana, Cuba. - Protein Kinase CK2 as emerging oncology target: Lessons from the CIGB-300 peptide inhibitor.
11:30-11:45 Coffe Break
Chairman: Frank Rauscher III (USA) and Dania Vázquez (Cuba)
11:45-12:05 Yasser Perera/ Center for Genetic Engineering and Biotechnology, Havana, Cuba. - Targeting of Protein Kinase CK2-mediated phoshorylation in Acute Myeloid Leukemia (AML).
12:10-12:30 Brizaida Oliva/ Center for Genetic Engineering and Biotechnology, Havana, Cuba - The strategy of targeting COMMD1 in cancer defines to CIGB-552 as anti-cancer drug.
12:35-13:00 Iraldo Bello/ Center for Genetic Engineering and Biotechnology, Havana, Cuba. - HeberFERON: Clinical impact in patients with non-melanoma skin cancer. The role of combinations of therapy in cancer.
Autoimmunity
Chairman: Willem van Eden and David Klatzmann
  Activity
8:30-9:15 David Klatzmann (France)-
9:20-9:50 Luis Graça (Portugal)- Tfh and Tfr cells in human autoimmunity
9:55-10:25 Willem van Eden (Netherlands) - Stress protein loaded tolDC: A novel ‘tolerance therapy’ for rheumatoid arthritis.
10:30-11:00 Maria del Carmen Dominguez (Cuba) - CIGB -814,  An Altered Peptide Ligand derived from Hsp60 as tolerance inductor for rheumatoid arthritis and other autoimmune diseases
11:05-11:20 Coffe Break
Chairman: Frank Rauscher III (USA) and Dania Vázquez (Cuba)
11:25-11:55 Maria Victoria Hernandez (Cuba)- Phase I clinical trial with CIGB-814: Safety, pharmacokinetics and preliminary therapeutic effects
12:00-12:30 Ana Maria Torres (Cuba) - CIGB-814 decreases anti-cyclic citrullinated peptides antibodies in patients with rheumatoid arthritis